Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

238 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA, Zaharoff S, King H, Evans S, Hamasaki T, Lodise T, Ghazaryan V, Beresnev T, Riccobene T, Patel R, Doernberg SB, Rappo U, Fowler VG Jr, Holland TL; Antibacterial Resistance Leadership Group (ARLG). Turner NA, et al. Among authors: lodise t. Trials. 2022 May 16;23(1):407. doi: 10.1186/s13063-022-06370-1. Trials. 2022. PMID: 35578360 Free PMC article.
An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection.
Kauf TL, McKinnon P, Corey GR, Bedolla J, Riska PF, Sims M, Jauregui-Peredo L, Friedman B, Hoehns JD, Mercier RC, Garcia-Diaz J, Brenneman SK, Ng D, Lodise T. Kauf TL, et al. Among authors: lodise t. BMC Infect Dis. 2015 Nov 7;15:503. doi: 10.1186/s12879-015-1261-9. BMC Infect Dis. 2015. PMID: 26547411 Free PMC article. Clinical Trial.
Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.
Doernberg SB, Lodise TP, Thaden JT, Munita JM, Cosgrove SE, Arias CA, Boucher HW, Corey GR, Lowy FD, Murray B, Miller LG, Holland TL; Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG). Doernberg SB, et al. Among authors: lodise tp. Clin Infect Dis. 2017 Mar 15;64(suppl_1):S24-S29. doi: 10.1093/cid/ciw828. Clin Infect Dis. 2017. PMID: 28350900 Free PMC article. Review.
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study).
Holland TL, O'Riordan W, McManus A, Shin E, Borghei A, File TM Jr, Wilcox MH, Torres A, Dryden M, Lodise T, Oguri T, Corey GR, McLeroth P, Shukla R, Huang DB. Holland TL, et al. Among authors: lodise t. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02580-17. doi: 10.1128/AAC.02580-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29530858 Free PMC article. Clinical Trial.
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
Huang DB, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, File TM Jr, Dryden M, Balser B, Desplats E, Torres A. Huang DB, et al. Among authors: lodise t. Int J Antimicrob Agents. 2018 Aug;52(2):233-240. doi: 10.1016/j.ijantimicag.2018.05.012. Epub 2018 May 19. Int J Antimicrob Agents. 2018. PMID: 29783024 Free article. Clinical Trial.
The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE).
Lodise TP, Rosenkranz SL, Finnemeyer M, Evans S, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, Schrank J, Bleasdale SC, Schultz S, Barron M, Stapleton A, Wray D, Chambers H, Fowler VG, Holland TL. Lodise TP, et al. Clin Infect Dis. 2020 Apr 10;70(8):1536-1545. doi: 10.1093/cid/ciz460. Clin Infect Dis. 2020. PMID: 31157370 Free PMC article.
A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections.
Noviello S, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, File TM, Dryden M, Balser B, Scaramucci A, Torres A, Huang DB. Noviello S, et al. Among authors: lodise t. J Med Microbiol. 2020 Apr;69(4):625-630. doi: 10.1099/jmm.0.001177. J Med Microbiol. 2020. PMID: 32195649 Free article. Clinical Trial.
238 results